May 9, 2022 01:51 PM EDT
Pharma
Marketing

Deep­In­tent ponies up ad guar­an­tees to take the edge off phar­mas' pro­gram­mat­ic ad hes­i­ta­tion

Beth Snyder Bulik

Senior Editor

Phar­ma com­pa­nies still lag oth­er in­dus­tries when it comes to pro­gram­mat­ic ad­ver­tis­ing use, but the promise of bet­ter tar­get­ing – and now ad guar­an­tees …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times